Your browser doesn't support javascript.
Long-term passaging of pseudo-typed SARS-CoV-2 reveals the breadth of monoclonal and bispecific antibody cocktails.
Ma, Hang; Zong, Hui-Fang; Liu, Jun-Jun; Yue, Ya-Li; Ke, Yong; Liao, Yun-Ji; Tang, Hao-Neng; Wang, Lei; Wang, Shu-Sheng; Yuan, Yun-Sheng; Wu, Ming-Yuan; Bian, Yan-Lin; Zhang, Bao-Hong; Yin, Hai-Yang; Jiang, Hua; Sun, Tao; Han, Lei; Xie, Yue-Qing; Zhu, Jian-Wei.
  • Ma H; Engineering Research Center of Cell and Therapeutic Antibody, Ministry of Education, Shanghai, 200240, China.
  • Zong HF; School of Pharmacy, Shanghai Jiao Tong University, Shanghai, 200240, China.
  • Liu JJ; School of Pharmaceutical Sciences, Southwest University, Chongqing, 400715, China.
  • Yue YL; Engineering Research Center of Cell and Therapeutic Antibody, Ministry of Education, Shanghai, 200240, China.
  • Ke Y; School of Pharmacy, Shanghai Jiao Tong University, Shanghai, 200240, China.
  • Liao YJ; Jecho Institute, Co., Ltd., Shanghai, 200240, China.
  • Tang HN; Engineering Research Center of Cell and Therapeutic Antibody, Ministry of Education, Shanghai, 200240, China.
  • Wang L; School of Pharmacy, Shanghai Jiao Tong University, Shanghai, 200240, China.
  • Wang SS; Engineering Research Center of Cell and Therapeutic Antibody, Ministry of Education, Shanghai, 200240, China.
  • Yuan YS; School of Pharmacy, Shanghai Jiao Tong University, Shanghai, 200240, China.
  • Wu MY; Engineering Research Center of Cell and Therapeutic Antibody, Ministry of Education, Shanghai, 200240, China.
  • Bian YL; School of Pharmacy, Shanghai Jiao Tong University, Shanghai, 200240, China.
  • Zhang BH; Engineering Research Center of Cell and Therapeutic Antibody, Ministry of Education, Shanghai, 200240, China.
  • Yin HY; School of Pharmacy, Shanghai Jiao Tong University, Shanghai, 200240, China.
  • Jiang H; Engineering Research Center of Cell and Therapeutic Antibody, Ministry of Education, Shanghai, 200240, China.
  • Sun T; School of Pharmacy, Shanghai Jiao Tong University, Shanghai, 200240, China.
  • Han L; Engineering Research Center of Cell and Therapeutic Antibody, Ministry of Education, Shanghai, 200240, China.
  • Xie YQ; School of Pharmacy, Shanghai Jiao Tong University, Shanghai, 200240, China.
  • Zhu JW; Jecho Laboratories, Inc., Frederick, MD, 21704, USA.
Acta Pharmacol Sin ; 44(7): 1455-1463, 2023 Jul.
Article in English | MEDLINE | ID: covidwho-2221797
ABSTRACT
The continuous emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants poses challenges to the effectiveness of neutralizing antibodies. Rational design of antibody cocktails is a realizable approach addressing viral immune evasion. However, evaluating the breadth of antibody cocktails is essential for understanding the development potential. Here, based on a replication competent vesicular stomatitis virus model that incorporates the spike of SARS-CoV-2 (VSV-SARS-CoV-2), we evaluated the breadth of a number of antibody cocktails consisting of monoclonal antibodies and bispecific antibodies by long-term passaging the virus in the presence of the cocktails. Results from over two-month passaging of the virus showed that 9E12 + 10D4 + 2G1 and 7B9-9D11 + 2G1 from these cocktails were highly resistant to random mutation, and there was no breakthrough after 30 rounds of passaging. As a control, antibody REGN10933 was broken through in the third passage. Next generation sequencing was performed and several critical mutations related to viral evasion were identified. These mutations caused a decrease in neutralization efficiency, but the reduced replication rate and ACE2 susceptibility of the mutant virus suggested that they might not have the potential to become epidemic strains. The 9E12 + 10D4 + 2G1 and 7B9-9D11 + 2G1 cocktails that picked from the VSV-SARS-CoV-2 system efficiently neutralized all current variants of concern and variants of interest including the most recent variants Delta and Omicron, as well as SARS-CoV-1. Our results highlight the feasibility of using the VSV-SARS-CoV-2 system to develop SARS-CoV-2 antibody cocktails and provide a reference for the clinical selection of therapeutic strategies to address the mutational escape of SARS-CoV-2.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Bispecific / COVID-19 Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Variants Limits: Humans Language: English Journal: Acta Pharmacol Sin Journal subject: Pharmacology Year: 2023 Document Type: Article Affiliation country: S41401-022-01043-w

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Bispecific / COVID-19 Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Variants Limits: Humans Language: English Journal: Acta Pharmacol Sin Journal subject: Pharmacology Year: 2023 Document Type: Article Affiliation country: S41401-022-01043-w